Back HCV Disease Progression Liver Cancer/HCC

Liver Cancer/HCC

AASLD 2017: Nivolumab Improves Outcomes in Liver Cancer Study

Nivolumab (Opdivo), a PD-1 checkpoint inhibitor that helps the immune system fight cancer, was associated with a decrease in tumor size or disease stabilization in patients with hepatocellular carcinoma (HCC) in the CheckMate 040 study, according to a report at the 2017 AASLD Liver Meeting last month in Washington, DC.

alt

Read more:

Coverage of the 2017 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Washington, DC, October 20-24, 2017.

Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.

Full coverage listing by topic

The Liver Meeting website

11/30/17

alt

FDA Approves Nivolumab Immunotherapy for Liver Cancer

In September, the U.S. Food and Drug Administration granted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumor activity, for people with hepatocellular carcinoma (HCC).

alt

Read more:

AASLD 2017: Curing Hepatitis C with DAAs Reduces Liver Cancer Risk

People who achieved a sustained virological response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, according to study results presented at the 2017 AASLD Liver Meeting last week in Washington, DC.

alt

 

Read more:

FDA Approves Nivolumab Immunotherapy for Liver Cancer

In September, the U.S. Food and Drug Administrationgranted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumor activity, for people with hepatocellular carcinoma (HCC).

alt

Read more: